Ultragenyx Pharmaceuticals Announces Initiation Of Phase 2 Study For Patients With Long-Chain Fatty Acid Oxidation Disorders
2/11/2014 9:37:13 AM
NOVATO, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been enrolled in an open-label Phase 2 study to assess safety and clinical effects of triheptanoin, also known as UX007, in patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to break down and convert long chain fatty acids into energy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by